Publications by authors named "Sanjana Chandrasekar"
Pharmacoecon Open
November 2024
Article Synopsis
- Bladder cancer incidence and mortality rates have remained stable over the past 20 years, with around 40% of high-risk nonmuscle invasive cases recurring or progressing.
- In 2021, an estimated 83,532 newly diagnosed bladder cancer patients in the USA faced treatment costs totaling approximately $2.6 billion, with costs varying significantly by disease stage.
- The economic analysis indicates that treating recurrent cases adds about $3.9 billion, leading to a total estimated treatment cost exceeding $6.5 billion for both newly diagnosed and recurrent patients, highlighting the financial impact of the disease.
